Showing 3481-3490 of 4164 results for "".
- Coave Therapeutics Announces Positive 12-Month Data from Ongoing Phase 1/2 Clinical Trial of Investigational RP Drughttps://modernod.com/news/coave-therapeutics-announces-positive-12-month-data-from-ongoing-phase-12-clinical-trial-of-investigational-rp-drug/2481640/Coave Therapeutics announced positive 12-month results from its phase 1/2 trial evaluating the safety and efficacy of its gene therapy, CTx-PDE6b, for retinitis pigmentosa (RP) caused by bi-allelic mutations in the PDE6B gene (PDE6b RP). These positive data support C
- Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for RP and LCA Gene Therapyhttps://modernod.com/news/ocugen-announces-fda-approval-for-enrollment-of-pediatric-patients-in-ongoing-ocu400-phase-12-clinical-trial-for-rp-and-lca-gene-therapy/2481499/Ocugen announced that the FDA approved enrolling pediatric patients in the ongoing OCU400 phase 1/2 trial. OCU400 is a gene therapy candidate for retinitis pigmentosa (RP) and Leber Congenital Amaurosis (LCA). “This approval moves us one step closer in our efforts to bri
- New Data Reveal Molecular Drivers of Thyroid Eye Disease (TED) May Remain Activated In Patients with Low Clinical Activity Score (CAS)https://modernod.com/news/new-data-reveal-molecular-drivers-of-thyroid-eye-disease-ted-may-remain-activated-in-patients-with-low-clinical-activity-score-cas/2481152/Horizon Therapeutics announced the presentation of new data defining molecular patterns in TED and further implicating the role of insulin-like growth factor-1 (IGF-1) in patients with low CAS. These data were presented during the American Academy of Ophthalmology Annual Meeting (
- EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMDhttps://modernod.com/news/eyepoint-pharmaceuticals-reports-positive-interim-safety-and-efficacy-data-from-phase-1-davio-clinical-trial-evaluating-eyp-1901-for-the-treatment-of-wet-amd/2480441/EyePoint Pharmaceuticals announced 6-month interim data from the “Durasert&nbs
- Kodiak Sciences Announces Presentation of Durability Data from Clinical Development Program of KSI-301 in Wet AMD, DME, and RVO at AAOhttps://modernod.com/news/kodiak-sciences-announces-presentation-of-durability-data-from-clinical-development-program-of-ksi-301-in-wet-amd-dme-and-rvo-at-aao/2476945/Kodiak Sciences announced that Charles C. Wykoff, MD, PhD, will present first-time results at the annual mneeting of the American Academy of Ophthalmology (AAO) to be held in San Francisco. The Retina Subspecialty Day (
- Ivantis Announces 3-Year Results from FDA Clinical Trial Demonstrating Long-Term Reduction of Severe Major Surgeries for Glaucoma Patientshttps://modernod.com/news/ivantis-announces-3-year-results-from-fda-clinical-trial-demonstrating-long-term-reduction-of-severe-major-surgeries-for-glaucoma-patients/2476534/Ivantis, developer of the Hydrus Microstent, announced the 3-year results from the HORIZON pivotal study. The 2-year results, which were the foundation of FDA approval, were presented in November 2017, and were recently published in the journal Ophthalmology.
- Iluvien Earns FDA Approval for Expansion to Treat Chronic Posterior Uveitishttps://modernod.com/news/iluvien-earns-fda-approval-for-expansion-to-treat-chronic-posterior-uveitis/2482704/ANI Pharmaceuticals announced that they the FDA has approved an expanded label for Iluvien to include treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). “Iluvien's expanded label and the strengthening of our pa
- Heidelberg Engineering Receives FDA Clearance for Spectralis Flex Module for Supine Imaginghttps://modernod.com/news/heidelberg-engineering-receives-fda-clearance-for-spectralis-flex-module-for-supine-imaging/2482486/Heidelberg Engineering has received FDA clearance for its Spectralis Flex Module, a multimodal diagnostic imaging platform. The new module is designed specifically for imaging the posterior segment of both pediatric and adult patients in a supine position, addressing a need for patients unab
- Carl Zeiss Meditec to Acquire Dutch Ophthalmic Research Center (DORC)https://modernod.com/news/carl-zeiss-meditec-to-acquire-dutch-ophthalmic-research-center-dorc/2482014/In a move to expand its position in the vitreo-retinal surgery segment and strengthen its position in the ophthalmic medical device category globally, Carl Zeiss Meditec announced it has entered into an agreement to acquire 100% of the shares in Dutch Ophthalmic Research Cente
- Alimera Acquires US Commercial Rights to Yutiqhttps://modernod.com/news/alimera-acquires-us-commercial-rights-to-yutiq/2481624/Alimera Sciences has acquired additional commercialization rights for Yutiq (fluocinolone acetonide intravitreal insert, 0.18mg) for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye from EyePoint Pharmaceuticals. Alimera now has exclusi